Chow Tai Fook
9
68M
9
0.10
3
1
- Areas of investment
Summary
In 1929 was created Chow Tai Fook, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Hong Kong. The fund was located in Asia if to be more exact in Hong Kong.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Chow Tai Fook, startups are often financed by SBCVC, Longitude Capital, Solborn Investment. The meaningful sponsors for the fund in investment in the same round are Varian Medical Systems, TRIREC, Solborn Investment. In the next rounds fund is usually obtained by United Overseas Bank, Suzhou Goldmantis Group, Share Capital.
The common things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this Corporate Investor is 13 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2014. The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. This Chow Tai Fook works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The average startup value when the investment from Chow Tai Fook is more than 1 billion dollars. The fund is constantly included in less than 2 investment rounds annually.
The overall number of key employees were 2.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Solar, Medical Device. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Alphaeon, Xiaoying Financial, Easyhin Technology. The fund has exact preference in some founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 9
- Lead investments
- 3
- Exits
- 1
- Rounds per year
- 0.10
- Investments by industry
- Medical (3)
- Manufacturing (2)
- Medical Device (2)
- Health Care (2)
- Financial Services (2) Show 23 more
- Investments by region
-
- China (5)
- United States (2)
- Singapore (1)
- New Zealand (1)
- Peak activity year
- 2015
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 190M
- Group Appearance index
- 0.67
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Elixir Clinical Research | 26 Apr 2022 | Biotechnology, Manufacturing, Medical, Pharmaceutical | Early Stage Venture | 52M | Shanghai, Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.